Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Avidity Biosciences, Inc. before investing.

In this article, we go over a few key elements for understanding Avidity Biosciences, Inc.’s stock price such as:

• Avidity Biosciences, Inc.’s current stock price and volume
• Why Avidity Biosciences, Inc.’s stock price changed recently
• Upgrades and downgrades for RNA from analysts
• RNA’s stock price momentum as measured by its relative strength

About Avidity Biosciences, Inc. (RNA)

Before we jump into Avidity Biosciences, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company’s pipeline has three programs in registrational clinical trials, such as Delpacibart etedesiran, which is in Phase 3 development stage for the treatment of people with myotonic dystrophy type 1; Delpacibart braxlosiran that is in Phase 1/2 development stage for treating facioscapulohumeral muscular dystrophy; and Delpacibart zotadirsen, which is in the Phase 2 EXPLORE44 open-label extension study for the treatment of Duchenne muscular dystrophy. The company is also developing precision cardiology candidates targeting rare genetic cardiomyopathies, including AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for protein kinase AMP-activated non-catalytic subunit gamma 2 syndrome. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Want to learn more about Avidity Biosciences, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Avidity Biosciences, Inc..

Avidity Biosciences, Inc.’s Stock Price as of Market Close

As of December 05, 2025, 4:00 PM, CST, Avidity Biosciences, Inc.’s stock price was $71.630.

Avidity Biosciences, Inc. is up 0.13% from its previous closing price of $71.540.

During the last market session, Avidity Biosciences, Inc.’s stock traded between $71.575 and $71.790. Currently, there are approximately 137.90 million shares outstanding for Avidity Biosciences, Inc..

Avidity Biosciences, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Avidity Biosciences, Inc. Stock Price History

Avidity Biosciences, Inc.’s (RNA) price is currently down 0.1% so far this month.

During the month of December, Avidity Biosciences, Inc.’s stock price has reached a high of $71.790 and a low of $71.120.

Over the last year, Avidity Biosciences, Inc. has hit prices as high as $71.790 and as low as $21.510. Year to date, Avidity Biosciences, Inc.’s stock is up 146.32%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Avidity Biosciences, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 05, 2025, there were 6 analysts who downgraded Avidity Biosciences, Inc.’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Avidity Biosciences, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Avidity Biosciences, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Avidity Biosciences, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Avidity Biosciences, Inc. (RNA) by visiting AAII Stock Evaluator.

Relative Price Strength of Avidity Biosciences, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 05, 2025, Avidity Biosciences, Inc. has a weighted four-quarter relative price strength of 22.11%, which translates to a Momentum Score of 92 and is considered to be Very Strong.

Want to learn more about how Avidity Biosciences, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Avidity Biosciences, Inc. Stock Price: Bottom Line

As of December 5, 2025, Avidity Biosciences, Inc.’s stock price is $71.630, which is up 0.13% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Avidity Biosciences, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.